Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

Halozyme Therapeutics is entering a powerful earnings inflection. FY25 revenue grew 38% to $1.397 billion. Check out why I am bullish on HALO stock.

Halozyme Therapeutics HALO reported fourth-quarter 2025 adjusted loss of 24 cents per share against the Zacks Consensus Estimate of earnings of $2.15. The company had reported adjusted earnings of $1.

Machado-Joseph disease causes sufferers to struggle with speech and movement as they lose control of their bodies.

MotoGP is on a mission to establish the motorsport as a “rock and roll” brand as it looks to ingrain itself into sports culture and appeal to a wider audience.

Consumer Analyst Group of New York Conference 2026 February 18, 2026 10:00 AM ESTCompany ParticipantsJacek Olczak ...

Between American president Donald Trump’s chaotic, fly-by-night tariff strategy and the ever-rising power demands of AI technology, it has long ...

Liquidity metrics and product diversification continue to influence valuation framing across clean energy equities.

The regulation overhaul makes cars shorter, narrower and lighter and could have a major impact on who crosses the line first.

Inside the world’s most luxurious FBOs and private air terminals offering spa suites, gourmet dining, and VIP service for ...

• A good road for sleds is now open on Mosquito gulch, nearly to the top of the pass, thus affording an easy inlet for ...

Greystone, a leading national commercial real estate finance company, has provided a $115,000,000 Freddie Mac loan to ...